Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Positive NEXICART-2 data and a well-supported $125M raise strengthen the balance sheet and de-risk the story, but the offering's dilution and the mid-2027 BLA timeline limit near-term upside; sentiment skews modestly positive.
Immix reported an 89% (40/45) complete response rate across all relapsed/refractory AL Amyloidosis patients in the Phase 2 NEXICART-2 trial, with all 25 newer patients in CR or MRD-negative and potential CR rate up to 98%. Strong efficacy and clean safety support the registrational path, a positive near-term sentiment driver for the stock.
SEC Filing (Form 8-K)Immix priced an 11.36M-share underwritten offering at $11.00 for ~$125M gross (~$117.1M net), with participation from Eventide, Janus Henderson, Ridgeback and Wellington. The raise funds NXC-201 development but introduces dilution, a near-term negative offset to the positive data.
SEC Filing (Form 8-K)Immix announced it will present at the 45th Annual J.P. Morgan Healthcare Conference (Jan 11-14, 2027). The stock rose 4.65% on the announcement day, reflecting investor interest in upcoming visibility, though the event itself is beyond the two-week window.
StockTitan